TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27721228
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg/d
Study: 12144586
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg daily for 4 weeks
Study: 28445354
Drug: Tumescent saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent saline solution with epinephrine (1:1 million) and lidocaine (0.05%) (group 2)
Study: 28445354
Drug: Tumescent saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent saline solution with epinephrine (1:1 million) (group 1)
Study: 26626301
Drug: Probiotics intervention
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics intervention (tablet A and tablet B)
Study: 24005139
Drug: Non steroid
Normalized name: Proctofoam 1% Non Steroid Hemorrhoidal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non steroid cream
Study: 24005139
Drug: Hydrocortisone Butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone Butyrate 0.1% Cream
Study: 17154745
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy plus manuals (NRT + MAN)
Study: 12649521
Drug: Approximately 2
Normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 2 hours of therapy per week for 22.9 weeks
Study: 12649521
Drug: Total of
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 98.4 hours of therapy
Study: 12649521
Drug: Total of
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 43.6 hours of therapy
Study: 12649521
Drug: Total length
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total length of therapy time
Study: 12649521
Drug: Hours of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hours of therapy provided in a week
Study: 12649521
Drug: Total number
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total number of hours of therapy
Study: 1576048
Drug: ICI 170,809
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 170,809 (7 mg)
Study: 2416331
Drug: Tofisopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofisopam (100 mg)
Study: 31878961
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving an educational intervention and continuing usual treatment
Study: 29431785
Drug: Glucono‐δ‐lactone (GDL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucono‐δ‐lactone (GDL) 2000 mg day‐1
Study: 20157833
Drug: Saline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.2 ml kg(‐1)
Study: 10599933
Drug: Valerian root
Normalized name: Valerian Root
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian root extract (VRE) 600 mg LI 156
Study: 10599933
Drug: Flunitrazepam (FNZ)
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (FNZ) 1 mg
Study: 7015844
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus antacid (Maalox)
Study: 25173770
Drug: Valerian root
Normalized name: Valerian Root
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian root extract (530 mg per capsule, 1,060 mg daily)
Study: 23736751
Drug: TIMT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMT + treatment as usual (TAU)
Study: 15481447
Drug: PBSC collection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBSC collection after intermediate-dose cytarabine and mitoxantrone (group B)
Study: 15481447
Drug: PBSC collection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBSC collection after induction and/or consolidation chemotherapy (group A)
Study: 8787684
Drug: Oltipraz 125
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 125 mg/m2
Study: 8787684
Drug: Oltipraz 250
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 250 mg/m2
Study: 2731461
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal containing 80 g complex carbohydrates
Study: 2731461
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal containing 140 g complex carbohydrates
Study: 30987685
Drug: m-health medication
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-health medication adherence intervention
Study: 25422825
Drug: 6-mm long
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm long implants
Study: 25422826
Drug: 10-mm long
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mm long implants
Study: 23194203
Drug: Propofol (25.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (25.5 µg/kg/minute)
Study: 11501687
Drug: Haloperidol (1.4±0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1.4±0.7 mg/day)
Study: 8244516
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg PO TID for 7 days)
Study: 2700702
Drug: Bromelaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelaine (3 x 80 mg daily for 6 days)
Study: 25881690
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Mitiglinide + Sitagliptin)
Study: 23883803
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid (Ns) + antihistamine (Ah)
Study: 23883803
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid (Ns)
Study: 28426856
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole
Study: 22042283
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous amphotericin B (AmB)
Study: 15660766
Drug: Zonisamide 500
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 500 mg/day
Study: 16316744
Drug: Zonisamide 400-600
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 400-600 mg/day
Study: 15013305
Drug: IV thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thymoglobulin (ATG 5 mg/kg/d) plus methylprednisolone (500 mg/d) plus azathiopurine (2 mg/kg/d) on days 0 and 1 after renal transplantation.
Study: 11312402
Drug: Atopic asthmatics
Normalized name: Atopica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopic asthmatics treated with beta(2) agonists alone
Study: 9562357
Drug: Salbutamol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.4 mg x 3) administered 10 min before exercise
Study: 29035633
Drug: Technology assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology assisted therapy for separation anxiety (TTSA)
Study: 22539545
Drug: Cilostazol treatment
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol treatment
Study: 28073668
Drug: Cilostazol-free treatment
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol-free treatment
Study: 23506518
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and postoperative physical therapy
Study: 19496829
Drug: Other active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other active agents
Study: 9291281
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with standardized cat dander extract
Study: 3105558
Drug: Astemizole 5
Normalized name: astemizole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 5 mg/d
Study: 3105558
Drug: Astemizole 20
Normalized name: astemizole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 20 mg/d
Study: 29587288
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium thiosulfate (IV STS) 12.5 g during the last HD hour twice weekly for 6 months
Study: 29587288
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium thiosulfate (IV STS)
Study: 25373724
Drug: Anodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal transcranial direct current stimulation (tDCS) combined with standard treatment
Study: 25373724
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with standard treatment
Study: 22575567
Drug: S(+)-ketamine pharmacodynamics
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)-ketamine pharmacodynamics
Study: 17390761
Drug: Fexofenadine HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine HCl, 180 mg
Study: 27349705
Drug: Pitavastatin monotherapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin monotherapy (target LDL-C 90-100mg/dL)
Study: 21996058
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (EX) - attended exercise facility three times/week for 52 weeks, daily jumping exercises at home, calcium supplementation.
Study: 11966923
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (Braun Oral‐B Plaque Remover 3‐D)
Study: 11966923
Drug: Manual soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual soft toothbrush (Oral‐B Squish‐grip brush)
Study: 1639941
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg cetrorelix
Study: 1639941
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg cetrorelix
Study: 1639941
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg cetrorelix
Study: 1639941
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg cetrorelix
Study: 1639941
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg cetrorelix
Study: 6089307
Drug: Enalapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (40 mg daily)
Study: 6089307
Drug: Lisinopril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (40 mg daily)
Study: 6089307
Drug: Both enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both enalapril and lisinopril
Study: 19483453
Drug: Intraperitoneal injection
Normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of 0.25% bupivacaine (40 ml) and 20 ml in 4 ports (5 ml each)
Study: 19483453
Drug: Intraperitoneal injection
Normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of 0.25% bupivacaine
Study: 11504277
Drug: Buspirone extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone extended-release (ER) formulation
Study: 9489934
Drug: Nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarette (0.8 mg nicotine)
Study: 2336928
Drug: 0.25% L-timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% L-timolol
Study: 7212475
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg dose of verapamil
Study: 28768334
Drug: Individual face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual face-to-face cognitive behavioral therapy (CBT)
Study: 10489005
Drug: Control Treatment
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control Treatment (CT)
Study: 23627650
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 60 µg alprostadil over 3 weeks
Study: 23627650
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion over 3 weeks
Study: 16715252
Drug: Topical levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical levofloxacin 0.5%
Study: 14739817
Drug: Basal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal group (12 ml/h basal, 0.05-ml patient-controlled bolus dose)
Study: 3684126
Drug: Tocolytic (ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic (ritodrine hydrochloride 200 micrograms/minute for 20 minutes via continuous intravenous infusion)
Study: 28826229
Drug: Provider-administered rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-administered rapid blood (finger-prick) HIV test (standard of care)
Study: 28826229
Drug: Choice between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice between SOC or a self-administered oral rapid HIV test with provider supervision
Study: 17370787
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 1.5 mg/kg
Study: 23800312
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg po daily for 3 months
Study: 16897271
Drug: Adjuvant intraportal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraportal infusion chemotherapy (IPIC) for patients with stage I and II disease.
Study: 16897271
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hepatectomy without adjuvant therapy).
Study: 10757152
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (1 g magnesium sulfate in pump prime plus 5 mmol/L in cardioplegic solution)
Study: 1487226
Drug: Gemfibrozil (G)
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil (G)
Study: 29672817
Drug: Intrapleural instillation
Normalized name: Talc Powder for intrapleural instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural instillation of 50 mL autologous blood 3 days after insertion of chest drain (Group A)
Study: 25483677
Drug: Tecemotide (L-BLP25)
Normalized name: L
DrugBank: Tecemotide (DB12568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecemotide (L-BLP25)
Study: 25483677
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple low doses of cyclophosphamide
Study: 22743596
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg bid)
Study: 19667251
Drug: olmesartan/azelnidipine (20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/azelnidipine (20.0 mg and 16.0 mg)
Study: 19667251
Drug: olmesartan/hydrochlorothiazide (20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/hydrochlorothiazide (20.0 mg and 12.5 mg)
Study: 9537210
Drug: SK&F107647 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F107647 (dose range 0.01 to 100 ng/kg)
Study: 7699836
Drug: SY5555 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 10 mg/kg
Study: 334216
Drug: Nomifensine 75
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine 75 mg alone
Study: 334216
Drug: Nomifensine 75
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine 75 mg with Clobazam 15 mg
Study: 28063876
Drug: Breakfast (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast (at least 15% of daily energy requirement before 8:30 a.m.)
Study: 22127708
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg belimumab plus standard therapy
Study: 22127708
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg belimumab plus standard therapy
Study: 22127708
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg belimumab
Study: 22127708
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg belimumab
Study: 17908055
Drug: Concomitant vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant vaccination with ZOSTAVAX and inactivated influenza vaccine
Study: 17908055
Drug: Sequential vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential vaccination with ZOSTAVAX and inactivated influenza vaccine
Study: 11600924
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (exercise program with ergonomic education, administered twice a week for four months)
Study: 3135204
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of slow-release terbutaline
Study: 14594020
Drug: Subcutaneous enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous enfuvirtide added to an optimized oral background antiretroviral regimen
Study: 14594020
Drug: Optimized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized oral background antiretroviral regimen
Study: 24858376
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TRP-rich protein hydrolysate
Study: 20718163
Drug: Liquid simethicone
Normalized name: simethicone Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid simethicone (2 ml in 60 ml of water)
Study: 12351481
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (10 IU of regular insulin)
Study: 12351481
Drug: Saline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline alone (50 ml saline)
Study: 21178926
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CON, LFT, HFT)
Study: 10329827
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injections (placebo)
Study: 7552560
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment teams
Study: 2117202
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (including recombinant t-PA and urokinase)
Study: 2117202
Drug: Recombinant t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant t-PA infusions
Study: 7388323
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (1000 units/1000 ml infusate) given intravenously
Study: 7388323
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low dose heparin (5000 units 8-hourly)
Study: 31798841
Drug: Management-selected change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management-selected change agents (MSCAs)
Study: 27284082
Drug: Active dose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active dose of methylene blue (195 mg)
Study: 27284082
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 mg)
Study: 19585317
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g L‐citrulline‐malate
Study: 8638790
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 micrograms/kg)
Study: 1992957
Drug: Filicol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filicol (9 g/d)
Study: 1992957
Drug: Gemfibrozil (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1.2 g/d)
Study: 6391497
Drug: pizotifen 1
Normalized name: Pizotifen 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pizotifen 1 mg
Study: 30851515
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + SIN (Methotrexate + Sinomenine) at a dose of 120 mg twice daily
Study: 30851515
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + LEF (Methotrexate + Leflunomide) at a dose of 20 mg once daily
Study: 26503762
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (12 IU morning and night, 24 IU per day for 5 weeks)
Study: 20123246
Drug: AFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFT plus medical therapy
Study: 17599852
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin (SSRI)
Study: 17599852
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion in ICU
Study: 2186220
Drug: Phthivazide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phthivazide 0.5 g three times a day for 15-20 days
Study: 30573719
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen trometamol + 8 mg thiocolchicoside
Study: 30573719
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen trometamol
Study: 30573719
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen trometamol + 4 mg thiocolchicoside
Study: 25923482
Drug: Cysteine-rich whey
Normalized name: Whey
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine-rich whey protein isolate (Immunocal®) 20 g/day